Lonza advances integrated DNA‑to‑IND programmes with acceleration, derisking and innovation

BrukerBruker showcases expanded microbiology diagnostics portfolio - Investing.com

BrukerBruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio at ASM Microbe 2026 - 巴士的報

Endpoints NewsADC Therapeutics' confirmatory data for Zynlonta muddied by death rates

Eli LillyEli Lilly continues genetic medicine push with $1.9bn Ascidian partnership - Pharmaceutical Technology

Eli LillyEli Lilly forms billion-dollar genetic kidney disease partnership with US biotech Ascidian Therapeutics - medwatch.com

FierceBiotechAlnylam pens $2B deal with Inceptive to transform siRNA design with AI pioneer

Samsung BiologicsGlobal firms tighten hold on Korea’s biopharma supply chain - KED Global

Endpoints NewsADC biotech Ona Therapeutics secures $86.6M in Series B raise

BioPharma DiveA Spanish biotech banks $87M to make differentiated ADCs

Lonza NewsLonza advances integrated DNA‑to‑IND programmes with acceleration, derisking and innovation - Manufacturing Chemist

PfizerModerna Outshines Pharma Giants Lilly, Merck and Pfizer With 43% Year-to-Date Surge - NAI500

ModernaHeated LNP litigation puts Moderna and Acuitas in the spotlight - Life Sciences Intellectual Property Review